Uni-Bio Science Acquires Global Rights to Type 2 Diabetes Drug Mitiglinide from Jiangsu Hansoh Pharmaceutical Co. Ltd
Strategic deal boosts Uni-Bio Science Group's growing diabetes treatment portfolio and accelerates preparation for the commercial launch of Uni-E4
HONG KONG, Nov 24, 2015 - (ACN Newswire) - Uni-Bio Science Group Limited ("Uni-Bio" or the "Group"; HKEx code: 690) today announced that it will acquire exclusive global rights to manufacture and commercialise mitiglinide, a new oral antidiabetic agent, from Jiangsu Hansoh Pharmaceutical Co. Ltd ("Hansoh").
| Uni-Bio Science Acquires Global Rights to Type 2 Diabetes Drug Mitiglinide from Jiangsu Hansoh Pharmaceutical Co. Ltd |
Mitiglinide is a new, oral antidiabetic agent which belongs to the glinides class of blood glucose lowering compounds. It is known to improve postprandial hyperglycemia in patients with Type 2 diabetes and has received New Drug Approval as a first and/or second line of treatment for the disease from the China Food and Drug Administration. In clinical studies, mitiglinide demonstrated a fast onset of action and was shown to be safe and effective with reduced gastrointestinal and cardiovascular side effects compared to other treatments in the same class. It is the market leader of the glinides class of Type 2 diabetes treatments in Japan, generating RMB900 million in revenue in 2014.
Hansoh has developed its own version of mitiglinide; it is currently being marketed and sold in China and Hansoh has successfully won a number of provincial tenders to date. Under the terms of agreement, Uni-Bio will acquire exclusive rights to distribute and commercialise Hansoh's mitiglinide globally and will manufacture the drug in its CGMP-certified plant in Beijing. Hansoh will continue to provide the active pharmaceutical ingredient to Uni-Bio.
Uni-Bio will begin to commercialise mitiglinide with immediate effect and will focus on building mitiglinide's market share across China, leveraging the strength of the Company's expanding sales team. In other markets Uni-Bio will seek distribution partners.
Worldwide, there are 387 million people living with diabetes*. China has the largest number of people with diabetes in the world and national diabetes prevalence currently stands at almost 100 million (approximately 8% of the population)*. If current trends continue, it is expected that 143 million people in China will have diabetes by 2035*. It is estimated that more than 50 million patients go undiagnosed, spurring the growth of the overall diabetes pharmaceutical markets in China to RMB20 billion in 2016**.
Mr. Kingsley Leung, Executive Director of Uni-Bio, said: "With the prevalence rate of diabetes reaching epidemic levels in China and across the world, there is a pressing need for a broad range of treatment options to manage this long-term chronic condition. Mitiglinide has been shown to be a safe and effective treatment of Type 2 diabetes with the potential to be best-in-class amongst glinides; it will be an important addition to our growing diabetes portfolio, enabling us to build upon our relationships with key stakeholders as we prepare for the commercial launch of Uni-E4."
"Our agreement with Hansoh supports our growth strategy and focus on in-licensing products which complement and enhance our current portfolio whilst also making an important contribution to revenue. Uni-Bio is increasingly recognised as a leading provider of high-quality healthcare treatments in China and we are excited to continue to build upon our success."
Uni-E4 is Uni-Bio's proprietary recombinant GLP-1 receptor agonist for the treatment of Type 2 diabetes which effectively regulates blood glucose level through stimulating insulin secretion and inhibiting glucagon release. Earlier this year, the Company released positive phase III results for Uni-E4, and plans to submit a New Drug Application to the China Food and Drug Administration in early 2016.
Dr. Lv Aifeng, Executive Vice President of Hansoh Pharmaceutical, said: "I am delighted that Hansoh Pharmaceutical has entered into this strategic agreement with Uni-Bio Science Group."
"Mitiglinide possesses unique therapeutic advantages, and China's diabetes market has immense opportunities with tremendous room for growth; we are confident that Uni-Bio has the capabilities to tap into and capture those opportunities to expand mitiglinides' market share in the country. This collaboration is a win-win for both companies."
*International Diabetes Federation **Bloomberg. China diabetes triples creating $3.2 billion drug market.
About Type 2 diabetes Type 2 diabetes mellitus (T2D) is a clinical syndrome, characterised by hyperglycemia, affecting 387 million people worldwide, of which more than 100 million people come from China. According to the International Diabetes Federation, China has the world's largest diabetes epidemic, and it continues to grow rapidly. It is estimated that China's diabetes treatment market will expand 20% annually to reach RMB20 billion by 2016, becoming one of the largest therapeutic areas in the PRC. With rising prevalence and an ageing population, there is a great demand for newer, safer and more cost effective T2D therapeutics.
About Uni-Bio Science Group Limited (SEHK: 0690) Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology.
About Jiangsu Hansoh Pharmaceutical Co., Ltd. Hansoh Pharmaceutical is an innovative pharmaceutical group engaged in the research and development, production and sale of drugs and biologics. It specialises in oncology, psychiatric treatment, endocrine systems, gastroenterology and infectious diseases. The Company operates top-class R&D centers with world-leading manufacturing and testing equipment and precision production facilities in New Jersey, U.S.A, Shanghai and Liangyungang, China. The Company has implemented a stringent quality assurance system that complies with international quality standards. It has an extensive sales network in China and a professional marketing team.
For more information, please contact:
Harvey Sun Director of Communications and Investor Relations Uni-Bio Science Group Tel: +852 3958 3181 harvey.sun@uni-bioscience.com
Daniel Zhi Business Development Director Jiangsu Hansoh Pharmaceuticals Tel: + 86 21 5191 7300 zhisd@hansoh.cn
Veron Ng/Angelus Lau Strategic Financial Relations Limited Tel: +852 2864 4800 sprg_unibio@sprg.com.hk
Source: Uni-Bio Science Group Limited Sectors: Daily Finance, Daily News, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore May 02, 2024 11:00 JST
| Sumitomo Metal Mining and Mitsubishi Corporation to Participate in Kalgoorlie Nickel Project - Goongarrie Hub Apr 30, 2024 19:08 JST
| New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg Apr 30, 2024 18:00 JST
| SPARX Group Establishes Space Frontiers Second Fund Apr 29, 2024 18:49 JST
| MHI Establishes Local Subsidiary "Mitsubishi Heavy Industries Vietnam" Apr 29, 2024 18:00 JST
| POSCO Future M and Honda Reach Basic Agreement on Collaboration for Production of Cathode Materials for Automotive Batteries in Canada Apr 29, 2024 14:25 JST
| Honda Plans to Establish Comprehensive Electric Vehicle Value Chain in Ontario, Canada Apr 29, 2024 14:16 JST
| JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan Apr 26, 2024 10:00 JST
| Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024 Apr 25, 2024 18:21 JST
| MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park Apr 25, 2024 17:45 JST
| GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series Apr 25, 2024 16:50 JST
| Toyota Exhibiting at Beijing Motor Show 2024 Apr 25, 2024 16:25 JST
| Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada Apr 25, 2024 11:10 JST
| UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh Apr 25, 2024 09:00 JST
| Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date Apr 24, 2024 17:19 JST
| MC and Denka Sign J/V Agreement in Fullerene Business Apr 24, 2024 17:02 JST
| Mitsubishi Motors Posts Record Sales in the Philippines in FY2023 Apr 24, 2024 13:56 JST
| NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance Apr 24, 2024 13:25 JST
| Fujitsu SX Survey reveals key success factors for sustainability Apr 23, 2024 10:25 JST
| Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions Apr 22, 2024 16:09 JST
|
More Latest Release >>
|